Companies · Biotech
Palo Alto · CA, USA; Remote · Biotech · founded 2012 · https://www.scienceexchange.com/
Diligence memoA one-page analyst read on Science Exchange — recommendation, valuation, rhythm, risks.→Science Exchange: limited disclosed financing to assess.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
Science Exchange is one of 233 Biotech companies tracked from Palo Alto, CA, USA; Remote, on record since 2012. By capital raised it ranks mid-pack (ahead of 67% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Powering scientific outsourcing
Science Exchange powers R&D outsourcing for the world’s top life sciences companies. Our marketplace gives scientists access to the innovation and research they need and our platform fully automates R&D outsourcing from source to pay so scientists can focus on what they love—science.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
No round amounts on record to chart.
No staged rounds to sequence.
Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 67% of sector peers (real $). Modeled value above 67% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| No rounds recorded. | |||||
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Science Exchange is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| 10x Science | Biotech | — | — | — | same sector |
| 1849 bio | Biotech | — | — | — | same sector |
| 1910 | Biotech | — | — | — | same sector |
| 20n | Biotech | — | — | — | same sector |
| 54Gene, Inc. | Biotech | Series B | $48.3M | $598.4M | same sector |
| Abacus Bioscience Inc. | Biotech | Series A | $4.4M | $46.6M | same sector |
| Abalone Bio | Biotech | — | — | — | same sector |
| Acoustic Wave Cell Therapy, Inc. | Biotech | Series A | $20.5M | $84.9M | same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| TetraScience, Inc. The only R&D data cloud for life sciences | Biotech | Series C | $72.1M | 76% |
| MedTech Exchange, Inc. | Healthtech | Series A | $56.6M | 76% |
| Benchling, Inc. Unlocking the power of biotech with modern software for modern science | Biotech | Series A | $253.2M | 75% |
| Tradewind BioScience Tradewind translates scientific insight into innovative ways of… | Biotech | — | — | 75% |
| Quartzy, Inc. Marketplace for life science supplies. | SaaS / Software | Series B | $173.0M | 75% |
| MantleBio Transform scientific data into discoveries | Biotech | — | — | 74% |
| Scispot The Best Data Infrastructure for Biotechs | Biotech | — | — | 74% |
| Science Corp | Other Technology | Series D+ | $1.7B | 73% |
See where Science Exchange sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Science Exchange, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.